Where is HUGEL located?

HUGEL is headquartered in Newport Beach, United States.

How many employees does HUGEL have?

As of May 31, 2026, the latest employee count at HUGEL is 191.

Is HUGEL a funded company?

HUGEL is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does HUGEL rank among its competitors?

HUGEL ranks 27th amongst 179 active competitors, of which 43 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Collplant, which secured $4M in Feb, 2026.

Who are the top competitors of HUGEL?

HUGEL's top competitors include Revance Therapeutics, Lineage Cell Therapeutics and Galderma. Among them, Collplant secured the most recent funding round in February, 2026.

HUGEL - 2026 Company Profile & Competitors

Company Details

Developer of aesthetic products for human skin. The company is focusing on the development and commercialization of botulinum toxin, hyaluronic acid fillers, and additional aesthetic portfolio products. The company's flagship product is injectable botulinum toxin treatment for glabellar lines.

Key Metrics

Founded Year

2021

Location

Newport Beach, United States

Stage

Unfunded

Ranked

27^th among 179 active competitors

Employee Count

191 as on May 31, 2026

Similar Companies

Revance Therapeutics & 235 more

View HUGEL's full profile

HUGEL has not raised any funding rounds yet.

HUGEL's employee count trend

HUGEL has 191 employees as of May 26. Here is HUGEL's employee count trend over the years:

Uncover HUGEL's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of HUGEL include Revance Therapeutics, Lineage Cell Therapeutics and Galderma. Here is the list of Top 10 competitors of HUGEL, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Revance Therapeutics 2002, Newark (United States), Acquired	Developer of neurotoxin aesthetic and therapeutic products for skin treatments	$155M	EW Healthcare Partners, Delphi Ventures & 16 others	70/100
2nd	Lineage Cell Therapeutics 1990, Carlsbad (United States), Public	Developer of cell based therapies for the treatment of cancer, eye disease and spinal disorders	$45.8M	State of California, Juvenescence & 4 others	65/100
3rd	Galderma 1981, Zug (Switzerland), Public	Manufacturer of products to treat a range of dermatological conditions	-	ADIA, Aisling Capital & 1 others	63/100
4th	Gero 2018, Singapore (Singapore), Series A	Developer of reverse engineering technology for controlling aging	$13.5M	Bulba Ventures, Melnichek Investments & 13 others	63/100
5th	Biofrontera 1997, Leverkusen (Germany), Public	Developer of therapies for actinic keratosis using photodynamic therapy	-	Rosalind Advisors, Deutsche Balaton & 1 others	62/100
6th	Dermavant 2016, Phoenix (United States), Acquired	Developer of small molecule based therapeutics for the treatment of inflammatory skin diseases	$160M	Marathon Asset Management, NovaQuest Capital Management ... Read more	61/100
7th	Sol-Gel Technologies 1998, United States, Public	Developing topical drug products for the treatment of rosacea, acne and interdigital tinea pedis.	$26M	Westwicke, Arkin Holdings & 6 others	59/100
8th	Hugel 2001, Chuncheon-si (South Korea), Acquired	Developer of therapeutics in the field of aesthetics	-	IMM Investment, SV Investment & 14 others	59/100
9th	Collplant 2004, Ness Ziona (Israel), Public	Developer of recombinant human collagen for regenerative medicine and aesthetics	$16.3M	Invesco, Pontifax & 4 others	59/100
10th	Evolus 2012, Irvine (United States), Public	Developer of aesthetic treatments and procedures	$500K	Daewoong Pharmaceutical, De novo ventures	58/100
27th	HUGEL 2021, Newport Beach (United States), Unfunded	Developer of aesthetic products for human skin	-	-	43/100